In order to investigate whether IL-7 therapy promotes tumor rejection, groups of OT-I-reconstituted Rag-/- mice received rIL-7 every 3–4 days for 18 days starting one day prior to adoptive T cell transfer. Here, IL7 is linked to neoplasm.